Clovis data competitive with AstraZeneca drug, says Citigroup

theflyonthewall.com

Citigroup views last night's data from Clovis (CLVS) as competitive with AstraZeneca's (AZN) AZD9291 in terms of efficacy and safety. Citi believes the lung cancer market is sizable enough to make both drugs big sellers and keeps a Buy rating on Clovis with a $109 price target.

View Comments (0)